Navigation Links
USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)
Date:3/10/2009

NEW YORK, March 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that the U.S. Patent and Trademark Office has issued a Notice of Final Determination granting the full five years of patent term extension for U.S. Patent No. 5,061,703 (the '703 Patent), which is listed in the U.S. Food and Drug Administration Orange Book for NAMENDA(R) (memantine hydrochloride). Forest has an exclusive license to the '703 patent from the German pharmaceutical company Merz Pharma. Forest and Merz have commenced patent litigation against several generic manufacturers who have filed ANDAs seeking FDA approval to market generic versions of NAMENDA. A trial in this litigation, pending in the U. S. District Court for the District of Delaware, is scheduled for April 2010. After review of the regulatory timeline for approval of NAMENDA(R) the U.S. Patent and Trademark Office determined that the '703 Patent is entitled to the full five years of patent term extension and will expire on April 11, 2015 instead of as originally anticipated on September 13, 2013.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Merz

Merz Pharmaceuticals researches, develops, produces and distributes innovative pharmaceutical products in the areas of neurology and psychiatry as well as in aesthetic dermatology and metabolism. In the area of Alzheimer's research, Merz Pharmaceuticals has achieved a leading position with the first active ingredient worldwide for the treatment of moderate to severe Alzheimer's disease. The company is headquartered in Frankfurt am Main, Germany. To learn more about Merz, visit www.merz.com.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
2. USPTO Confirms Validity of Bystolic(R) Patent
3. Guru Program Pioneered by Tom Gable Receives Official Registration from USPTO
4. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
5. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
7. American Red Cross Issues Blood Supply Alert
8. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
9. New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
10. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
11. Audio: New Survey Finds Strong Public Interest in Prescription Drug Safety Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American ... pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in a ...
(Date:4/24/2017)... Boulder, CO (PRWEB) , ... April 24, 2017 ... ... 2017 American Educational Research Association’s Outstanding Public Communication of Education Research Award. The ... the public, including education communities. It recognizes a scholar who has demonstrated the ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking into ... depicts every parent’s worst nightmare, when her three children were violently taken from her. ... my divorce,” James said. “After the death of my children, I continued to journal. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a ... hours a day, Quick Care provides patients with the option to request and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, ... Rod has been at the forefront of Gardant since it was founded in 1999. ... overseen the opening of more than 40 new senior living communities. With his leadership, ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... April 21, 2017 Halo Labs announces the ... particle analysis system called the Horizon at PEGS 2017 ... The new system analyzes sub visible particulate matter in ... particle screening as early as candidate selection and pre-formulation. ... biopharma contract research organization Elion Labs for ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
Breaking Medicine Technology: